Search
Neuraxis Inc
NRXSAdd to Watchlist
7.440USD
+0.130+1.78%
Market hours 09/24, 12:01（ET）
92.11MMarket Cap
LossP/E TTM
About Neuraxis Inc Company
Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company’s second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.
Neuraxis Inc Profile
Ticker SymbolNRXS
Company nameNeuraxis Inc
IPO dateAug 09, 2023
CEOCarrico (Brian Allen)
Number of employees21
Security typeOrdinary Share
Fiscal year-endAug 09
Address11611 N. Meridian St
CityCARMEL
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code46032
Phone18126890791
Websitehttps://neuraxis.com/
Ticker SymbolNRXS
IPO dateAug 09, 2023
CEOCarrico (Brian Allen)
Company Executives of Neuraxis Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher Robin (Chris) Brown
Dr. Christopher Robin (Chris) Brown
Director
Director
1.04M
--
Dr. Christopher Robin (Chris) Brown
Dr. Christopher Robin (Chris) Brown
Director
Director
1.04M
--
Dr. Christopher Robin (Chris) Brown
Dr. Christopher Robin (Chris) Brown
Director
Director
1.04M
--
Dr. Adrian Miranda
Dr. Adrian Miranda
Chief Medical Officer, Senior Vice President - Science and Technology
Chief Medical Officer, Senior Vice President - Science and Technology
199.11K
--
Dr. Adrian Miranda
Dr. Adrian Miranda
Chief Medical Officer, Senior Vice President - Science and Technology
Chief Medical Officer, Senior Vice President - Science and Technology
199.11K
--
Dr. Adrian Miranda
Dr. Adrian Miranda
Chief Medical Officer, Senior Vice President - Science and Technology
Chief Medical Officer, Senior Vice President - Science and Technology
199.11K
--
Ms. Kristin A. Ferge
Ms. Kristin A. Ferge
Independent Director
Independent Director
67.07K
+46.42%
Ms. Kristin A. Ferge
Ms. Kristin A. Ferge
Independent Director
Independent Director
67.07K
+46.42%
Ms. Kristin A. Ferge
Ms. Kristin A. Ferge
Independent Director
Independent Director
67.07K
+46.42%
Mr. Brian Carrico
Mr. Brian Carrico
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher Robin (Chris) Brown
Dr. Christopher Robin (Chris) Brown
Director
Director
1.04M
--
Dr. Christopher Robin (Chris) Brown
Dr. Christopher Robin (Chris) Brown
Director
Director
1.04M
--
Dr. Christopher Robin (Chris) Brown
Dr. Christopher Robin (Chris) Brown
Director
Director
1.04M
--
Dr. Adrian Miranda
Dr. Adrian Miranda
Chief Medical Officer, Senior Vice President - Science and Technology
Chief Medical Officer, Senior Vice President - Science and Technology
199.11K
--
Dr. Adrian Miranda
Dr. Adrian Miranda
Chief Medical Officer, Senior Vice President - Science and Technology
Chief Medical Officer, Senior Vice President - Science and Technology
199.11K
--
Dr. Adrian Miranda
Dr. Adrian Miranda
Chief Medical Officer, Senior Vice President - Science and Technology
Chief Medical Officer, Senior Vice President - Science and Technology
199.11K
--
FAQs
Who are the top five shareholders of Neuraxis Inc?
The top five shareholders of Neuraxis Inc are: Dr. Christopher Robin (Chris) Brown
How many institutions hold shares of Neuraxis Inc (NRXS)?
As of 2026Q1, 37 institutions hold shares of Neuraxis Inc, with a combined market value of approximately 2.57M, accounting for 22.68% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -553807.00.